{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:00:57Z","timestamp":1780437657819,"version":"3.54.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02271-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:16:59Z","timestamp":1780391819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Tregs to tissue remodelling: FOXP3 and IL-35 in the inflammatory landscape of nasal polyps"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9112-0582","authenticated-orcid":false,"given":"Gnanasoundari","family":"Gokulakannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-2295","authenticated-orcid":false,"given":"Nur Asyilla","family":"Che Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-5889","authenticated-orcid":false,"given":"Ramlah","family":"Kadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-321X","authenticated-orcid":false,"given":"Ramiza Ramza","family":"Ramli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9138-9215","authenticated-orcid":false,"given":"Baharudin","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmawati","family":"Lambuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2192-9751","authenticated-orcid":false,"given":"Norasnieda","family":"Md Shukri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2271_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.401","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1\u2013464.","journal-title":"Rhinology"},{"key":"2271_CR2","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jaci.2015.10.009","volume":"136","author":"WW Stevens","year":"2015","unstructured":"Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015;136:1442\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ni1247","volume":"6","author":"B Zhou","year":"2005","unstructured":"Zhou B, Comeau MR, De Smedt T, Liggitt HD, Dahl ME, Lewis DB, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6:1047\u201353.","journal-title":"Nat Immunol"},{"key":"2271_CR4","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/j.1398-9995.2006.01225.x","volume":"61","author":"T Van Zele","year":"2006","unstructured":"Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61:1280\u20139.","journal-title":"Allergy"},{"key":"2271_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/ACI.0b013e3282f4178f","volume":"8","author":"C Bachert","year":"2008","unstructured":"Bachert C, Zhang N, Patou J, Van Zele T, Gevaert P. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol. 2008;8:34\u20138.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2271_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","volume":"12","author":"RP Schleimer","year":"2017","unstructured":"Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12:331\u201357.","journal-title":"Annu Rev Pathol"},{"key":"2271_CR7","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","volume":"15","author":"C Bachert","year":"2024","unstructured":"Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S, et al. The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol. 2024;15:1356298.","journal-title":"Front Immunol"},{"key":"2271_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"2271_CR9","doi-asserted-by":"crossref","unstructured":"Ahern S, Cervin A. Inflammation and endotyping in chronic rhinosinusitis: a paradigm shift. Medicina (Kaunas). 2019;55(4):95.","DOI":"10.3390\/medicina55040095"},{"key":"2271_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.chest.2019.04.101","volume":"156","author":"A Kato","year":"2019","unstructured":"Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. Chest. 2019;156:141.","journal-title":"Chest"},{"key":"2271_CR11","unstructured":"SR Naik, SM Wala. Inflammation, allergy and asthma, complex immune origin diseases: mechanisms and therapeutic agents. Recent Patents Inflamm Allergy Drug Discov 2013; https:\/\/www.ingentaconnect.com\/content\/ben\/iad\/2013\/00000007\/00000001\/art00006"},{"key":"2271_CR12","doi-asserted-by":"crossref","unstructured":"Y Adir, M Al-Ahmad, CA Celis-Preciado, FD Colodenco, P Giavina-Bianchi ER. Type 2 inflammation in asthma and other airway diseases. J open Res. 2022. https:\/\/publications.ersnet.org\/content\/erjor\/8\/3\/00576-2021?ctkey=shareline&utm_medium=cpc&utm_source=TrendMD&utm_campaign=ERJ_Open_Res_TrendMD_1","DOI":"10.1183\/23120541.00576-2021"},{"issue":"6","key":"2271_CR13","first-page":"783","volume":"57","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang GH. Research advances in endotypes and precision medicine of chronic rhinosinusitis. Zhonghua er bi yan hou tou jing wai ke za zhi=. Chin J Otorhinolaryngol Head Neck Surg. 2022;57(6):783\u20138.","journal-title":"Chin J Otorhinolaryngol Head Neck Surg"},{"key":"2271_CR14","unstructured":"Fertin C, Nicolas JF, Gillery P, Kalis B, Banchereau J, Maquart FX. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cellular Mol Biol 1991;31:823\u20139 https:\/\/europepmc.org\/article\/med\/1807791"},{"key":"2271_CR15","doi-asserted-by":"publisher","unstructured":"Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2016;56:219\u201333. https:\/\/doi.org\/10.1007\/s12016-018-8712-1","DOI":"10.1007\/s12016-018-8712-1"},{"key":"2271_CR16","unstructured":"Heffler E, Blasi F, Latorre M, FM-TJ of A. The severe asthma network in Italy: findings and perspectives. The J Allergy Clin Immunol Pract. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213219818306731"},{"key":"2271_CR17","doi-asserted-by":"publisher","unstructured":"Zurawski S Jr, Huyghe F, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin\u20104 are complex and share a novel component that functions in signal transduction. EMBO J. 1993;12:2663\u201370. https:\/\/doi.org\/10.1002\/j.1460-2075.1993.tb05927.x","DOI":"10.1002\/j.1460-2075.1993.tb05927.x"},{"key":"2271_CR18","unstructured":"Immunology JF-NR. Type 2 inflammation in asthma\u2014present in most, absent in many. Rev Immunol. 2015; Available from: https:\/\/www.nature.com\/articles\/nri3786"},{"key":"2271_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nm1332","volume":"12","author":"S Fichtner-Feigl","year":"2006","unstructured":"Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13\u03b12 receptor is involved in induction of TGF-\u03b21 production and fibrosis. Nat Med. 2006;12:99\u2013106.","journal-title":"Nat Med"},{"key":"2271_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/1744666X.2020.1672538","volume":"15","author":"HH Kariyawasam","year":"2019","unstructured":"Kariyawasam HH, Gane SB. Allergen-induced asthma, chronic rhinosinusitis and transforming growth factor-\u03b2 superfamily signaling: mechanisms and functional consequences. Expert Rev Clin Immunol. 2019;15:1155\u201370.","journal-title":"Expert Rev Clin Immunol"},{"key":"2271_CR21","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jaci.2007.12.286","volume":"121","author":"VANBRUAENE N","year":"2008","unstructured":"VANBRUAENE N. T cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008;121:S72\u201372.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/ni0608-588","volume":"9","author":"A O\u2019Garra","year":"2008","unstructured":"O\u2019Garra A, Stockinger B, Veldhoen M. Differentiation of human T(H)-17 cells does require TGF-beta! Nat Immunol. 2008;9:588\u201390.","journal-title":"Nat Immunol"},{"key":"2271_CR23","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1172\/JCI1112","volume":"101","author":"VA Fadok","year":"1998","unstructured":"Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890\u20138.","journal-title":"J Clin Invest"},{"key":"2271_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1084\/jem.179.3.1041","volume":"179","author":"R Alam","year":"1994","unstructured":"Alam R, Forsythe P, Stafford S, Fukuda Y. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med. 1994;179:1041\u20135.","journal-title":"J Exp Med"},{"key":"2271_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1046\/j.1365-2567.2001.01185.x","volume":"102","author":"HK Sillett","year":"2001","unstructured":"Sillett HK, Cruickshank SM, Southgate J, Trejdosiewicz LK. Transforming growth factor-beta promotes death by neglect in post-activated human T cells. Immunology. 2001;102:310\u20136.","journal-title":"Immunology"},{"key":"2271_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1631\/jzus.B1700346","volume":"19","author":"S Zhao","year":"2018","unstructured":"Zhao S, Wang C. Regulatory T cells and asthma. J Zhejiang Univ B. 2018;19:663\u201373. . https:\/\/doi.org\/10.1631\/jzus.B1700346","journal-title":"J Zhejiang Univ B"},{"key":"2271_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2022.12.826","volume":"151","author":"ME Kotas","year":"2023","unstructured":"Kotas ME, Patel NN, Cope EK, Gurrola JG, Goldberg AN, Pletcher SD, et al. IL-13\u2013associated epithelial remodeling correlates with clinical severity in nasal polyposis. J Allergy Clin Immunol. 2023;151:1277\u201385.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jaci.2023.03.023","volume":"152","author":"WE LeSuer","year":"2023","unstructured":"LeSuer WE, Kienzl M, Ochkur SI, Schicho R, Doyle AD, Wright BL, et al. Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice. J Allergy Clin Immunol. 2023;152:469\u2013e48510.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0167-5699(99)01522-4","volume":"20","author":"JC Guti\u00e9rrez-Ramos","year":"1999","unstructured":"Guti\u00e9rrez-Ramos JC, Lloyd C, Gonzalo JA, Eotaxin. From an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today. 1999;20:500\u20134.","journal-title":"Immunol Today"},{"key":"2271_CR30","doi-asserted-by":"publisher","first-page":"108082","DOI":"10.1016\/j.rmed.2025.108082","volume":"241","author":"F Chen","year":"2025","unstructured":"Chen F, Yu C, Zhang T, Shen C, Li Y, Zhang H. Age-related changes of inflammatory cytokines in nasal secretion of patients with chronic rhinosinusitis. Respir Med. 2025;241:108082.","journal-title":"Respir Med"},{"key":"2271_CR31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/eji.201546095","volume":"46","author":"X Wang","year":"2016","unstructured":"Wang X, Wei Y, Xiao H, Liu X, Zhang Y, Han G, et al. A novel IL-23p19\/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice. Eur J Immunol. 2016;46:1343.","journal-title":"Eur J Immunol"},{"key":"2271_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19:665\u201373.","journal-title":"Nat Immunol"},{"key":"2271_CR33","doi-asserted-by":"publisher","first-page":"e13092","DOI":"10.1111\/and.13092","volume":"50","author":"P Jacobo","year":"2018","unstructured":"Jacobo P. The role of regulatory T Cells in autoimmune orchitis. Andrologia. 2018;50:e13092.","journal-title":"Andrologia"},{"key":"2271_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2016.07.006","volume":"166","author":"J van der Veeken","year":"2016","unstructured":"van der Veeken J, Gonzalez AJ, Cho H, Arvey A, Hemmers S, Leslie CS, et al. Memory of inflammation in regulatory T cells. Cell. 2016;166:977.","journal-title":"Cell"},{"key":"2271_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/83713","volume":"27","author":"CL Bennett","year":"2001","unstructured":"Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20\u20131.","journal-title":"Nat Genet"},{"key":"2271_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/cei.13288","volume":"197","author":"A Mohr","year":"2019","unstructured":"Mohr A, Atif M, Balderas R, Gorochov G, Miyara M. The role of FOXP3\u2009+\u2009regulatory T cells in human autoimmune and inflammatory diseases. Clin Exp Immunol. 2019;197:24\u201335.","journal-title":"Clin Exp Immunol"},{"key":"2271_CR37","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: How do they suppress immune responses? Int Immunol. 2009;21:1105\u201311.","journal-title":"Int Immunol"},{"key":"2271_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.molmed.2012.06.001","volume":"18","author":"M Da Silva Martins","year":"2012","unstructured":"Da Silva Martins M, Piccirillo CA. Functional stability of Foxp3\u2009+\u2009regulatory T cells. Trends Mol Med. 2012;18:454\u201362.","journal-title":"Trends Mol Med"},{"key":"2271_CR39","doi-asserted-by":"publisher","first-page":"1055466","DOI":"10.3389\/fimmu.2022.1055466","volume":"13","author":"JM Sanders","year":"2022","unstructured":"Sanders JM, Jeyamogan S, Mathew JM, Leventhal JR. Foxp3\u2009+\u2009regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation. Front Immunol. 2022;13:1055466.","journal-title":"Front Immunol"},{"key":"2271_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2500\/ajra.2017.31.4472","volume":"31","author":"C Palmer","year":"2017","unstructured":"Palmer C, Mulligan JK, Smith SE, Atkinson C. The role of regulatory T cells in the regulation of upper airway inflammation. Am J Rhinol Allergy. 2017;31:345.","journal-title":"Am J Rhinol Allergy"},{"key":"2271_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109\u201318.","journal-title":"Cell Res"},{"key":"2271_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/cei\/uxac105","volume":"211","author":"F Harris","year":"2022","unstructured":"Harris F, Berdugo YA, Tree T. IL-2-based approaches to Treg enhancement. Clin Exp Immunol. 2022;211:149.","journal-title":"Clin Exp Immunol"},{"key":"2271_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","volume":"490","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. FoxP3\u2009+\u2009T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174\u201385.","journal-title":"Cancer Lett"},{"key":"2271_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.apcsb.2019.11.010","volume":"121","author":"J Huang","year":"2020","unstructured":"Huang J, Wang S, Jia Y, Zhang Y, Dai X, Li B. Targeting FOXP3 complex ensemble in drug discovery. Adv Protein Chem Struct Biol. 2020;121:143\u201368.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"2271_CR45","doi-asserted-by":"crossref","unstructured":"Schmidl C, Hansmann L, Blood TL, PJ Balwierz, H Kawaji, M Itoh, J KawaiBlood, J Am Soc Hematol. The enhancer and promoter landscape of human regulatory and conventional Tcell subpopulations. https:\/\/ashpublications.org\/blood\/article-abstract\/123\/17\/e68\/32567","DOI":"10.1182\/blood-2013-02-486944"},{"key":"2271_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.smim.2011.10.002","volume":"23","author":"T Yamaguchi","year":"2011","unstructured":"Yamaguchi T, immunology Wing JSS-S. in, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3+ regulatory T cells under inflammatory or non-inflammatory conditions. Seminar Immunol. 2011;23: 424\u201330 https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1044532311001175","journal-title":"Seminar Immunol"},{"key":"2271_CR47","doi-asserted-by":"crossref","unstructured":"Brunkow M, Jeffery E, Hjerrild K, Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE. Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27, 68\u201373 (2001). Available from: https:\/\/www.nature.com\/articles\/ng0101_68","DOI":"10.1038\/83784"},{"key":"2271_CR48","doi-asserted-by":"crossref","unstructured":"Wildin R, Ramsdell F, Peake J. FF-N, RS Wildin, F Ramsdell, J Peake, F Faravelli, JL Casanova, N Buist, E Levy-Lahad X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18\u201320 https:\/\/www.nature.com\/articles\/ng0101_18","DOI":"10.1038\/83707"},{"key":"2271_CR49","doi-asserted-by":"crossref","unstructured":"Bennett C, Christie J, Ramsdell F, MB-N, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27, 20\u201321 (2001). https:\/\/www.nature.com\/articles\/ng0101_20","DOI":"10.1038\/83713"},{"key":"2271_CR50","first-page":"227","volume":"42","author":"M Dupage","year":"2015","unstructured":"Dupage M, Chopra G, Marson A, Correspondence JAB, Quiros J, Rosenthal WL, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, TurkaImmunity L, et al. 2015\u2022cell com. 2015;42:227\u201338.","journal-title":"2015\u2022cell com"},{"key":"2271_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2012.05.031","volume":"150","author":"RM Samstein","year":"2012","unstructured":"Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell. 2012;150:29\u201338.","journal-title":"Cell"},{"key":"2271_CR52","doi-asserted-by":"crossref","unstructured":"Haribhai D, Williams J, Jia S, Nickerson D. Requisite role for induced regulatory t cells in tolerance based on expanding antigen receptor diversity.Immunity. 2011;35:109-122","DOI":"10.1016\/j.immuni.2011.03.029"},{"key":"2271_CR53","first-page":"36","volume":"197","author":"M Attias","year":"2019","unstructured":"Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3\u2009+\u2009Treg cell development and function in health and disease. Acad Attias T Al-Aubodah CA PiccirilloClinical Exp Immunol. 2019;197:36\u201351.","journal-title":"Acad Attias T Al-Aubodah CA PiccirilloClinical Exp Immunol"},{"key":"2271_CR54","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1073\/pnas.0811556106","volume":"106","author":"N Komatsu","year":"2009","unstructured":"Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3\u2009+\u2009T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A. 2009;106:1903\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2271_CR55","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/eji.200839196","volume":"39","author":"JH Duarte","year":"2009","unstructured":"Duarte JH, Zelenay S, Bergman M-L, Martins AC, Demengeot J, Zel ML, Bergman AC, Martins. J DemengeotEuropean J Immunol 2009\u2022Wiley Online Libr. 2009;39:948\u201355. https:\/\/doi.org\/10.1002\/eji.200839196.","journal-title":"J DemengeotEuropean J Immunol 2009\u2022Wiley Online Libr"},{"key":"2271_CR56","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"J Fontenot","year":"2003","unstructured":"Fontenot J, Gavin M, Rudensky A. AY Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136. . https:\/\/www.nature.com\/articles\/ni904","journal-title":"Nat Immunol"},{"key":"2271_CR57","doi-asserted-by":"publisher","first-page":"15709","DOI":"10.3390\/ijms232415709","volume":"23","author":"W Zysk","year":"2022","unstructured":"Zysk W, Gle\u0144 J, Trzeciak M. Current insight into the role of IL-35 and its potential involvement in the pathogenesis and therapy of atopic dermatitis. Int J Mol Sci. 2022;23:15709.","journal-title":"Int J Mol Sci"},{"key":"2271_CR58","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13287-018-0988-9","volume":"9","author":"H Guo","year":"2018","unstructured":"Guo H, Li B, Wang W, Zhao N, Gao H. Mesenchymal stem cells overexpressing IL-35: a novel immunosuppressive strategy and therapeutic target for inducing transplant tolerance. Stem Cell Res Ther. 2018;9:254.","journal-title":"Stem Cell Res Ther"},{"key":"2271_CR59","doi-asserted-by":"publisher","first-page":"655114","DOI":"10.3389\/fphar.2021.655114","volume":"12","author":"PL Xin","year":"2021","unstructured":"Xin PL, Jie LF, Cheng Q, Bin DY, Dan CW. Pathogenesis and function of interleukin-35 in rheumatoid arthritis. Front Pharmacol. 2021;12:655114.","journal-title":"Front Pharmacol"},{"key":"2271_CR60","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature12979","volume":"507","author":"P Shen","year":"2014","unstructured":"Shen P, Roch T, Lampropoulou V, O\u2019Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366\u201370.","journal-title":"Nature"},{"key":"2271_CR61","unstructured":"Collison L, Workman C, Kuo T, Boyd K, Nature YW. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Available. from: https:\/\/www.nature.com\/articles\/nature06306"},{"key":"2271_CR62","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.coi.2009.09.011","volume":"21","author":"M Bettini","year":"2009","unstructured":"Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol. 2009;21:612\u20138.","journal-title":"Curr Opin Immunol"},{"key":"2271_CR63","doi-asserted-by":"publisher","first-page":"12041","DOI":"10.1073\/pnas.94.22.12041","volume":"94","author":"O Devergne","year":"1997","unstructured":"Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A. 1997;94:12041\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2271_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12026-011-8209-y","volume":"51","author":"LL Jones","year":"2011","unstructured":"Jones LL, Vignali DAA. Molecular interactions within the IL-6\/IL-12 cytokine\/receptor superfamily. Immunol Res. 2011;51:5.","journal-title":"Immunol Res"},{"key":"2271_CR65","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fimmu.2013.00315","volume":"4","author":"BM Olson","year":"2013","unstructured":"Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol. 2013;4:315.","journal-title":"Front Immunol"},{"key":"2271_CR66","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2018.01.017","volume":"17","author":"LC Su","year":"2018","unstructured":"Su LC, Liu XY, Huang AF, Xu WD. Emerging role of IL-35 in inflammatory autoimmune diseases. Autoimmun Rev. 2018;17:665\u201373.","journal-title":"Autoimmun Rev"},{"key":"2271_CR67","doi-asserted-by":"publisher","first-page":"569575","DOI":"10.3389\/fphar.2020.569575","volume":"11","author":"S Hu","year":"2021","unstructured":"Hu S, Lian PP, Hu Y, Zhu XY, Jiang SW, Ma Q, et al. The role of IL-35 in the pathophysiological processes of liver disease. Front Pharmacol. 2021;11:569575.","journal-title":"Front Pharmacol"},{"key":"2271_CR68","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature06306","volume":"450","author":"LW Collison","year":"2007","unstructured":"Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566\u20139.","journal-title":"Nature"},{"key":"2271_CR69","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","volume":"45","author":"ME Turnis","year":"2015","unstructured":"Turnis ME, Andrews LP, Vignali DAA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45:1892\u2013905.","journal-title":"Eur J Immunol"},{"key":"2271_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-065X.2008.00704.x","volume":"226","author":"LW Collison","year":"2008","unstructured":"Collison LW, Vignali DAA. Interleukin-35: Odd one out or part of the family? Immunol Rev. 2008;226:248\u201362.","journal-title":"Immunol Rev"},{"key":"2271_CR71","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00405-022-07640-z","volume":"280","author":"Y Cao","year":"2022","unstructured":"Cao Y, Hu X, Zhou C, Zhao K, Zheng Y, Jiang W, et al. Increased IL-1\u03b1 expression in chronic rhinosinusitis with nasal polyps. Eur Arch Oto-Rhino-Laryngology. 2022;280:1209.","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"key":"2271_CR72","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/eji.200737810","volume":"37","author":"W Niedbala","year":"2007","unstructured":"Niedbala W, Wei X-Q, Cai B, Hueber AJ, Leung BP, McInnes IB. IL-35 is a novel cytokine with therapeutic effects against collagen\u2010induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37:3021\u20139. https:\/\/doi.org\/10.1002\/eji.200737810","journal-title":"Eur J Immunol"},{"key":"2271_CR73","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni.1952","volume":"11","author":"LW Collison","year":"2010","unstructured":"Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11:1093\u2013101.","journal-title":"Nat Immunol"},{"key":"2271_CR74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/alr.22234","volume":"9","author":"W Wang","year":"2019","unstructured":"Wang W, Gao Y, Zhu Z, Zha Y, Wang X, Qi F, et al. Changes in the clinical and histological characteristics of Chinese chronic rhinosinusitis with nasal polyps over 11 years. Int Forum Allergy Rhinol. 2019;9:149\u201357.","journal-title":"Int Forum Allergy Rhinol"},{"key":"2271_CR75","doi-asserted-by":"crossref","unstructured":"Ye Z, Jiang Y, Sun D, Zhong W, Zhao L, reports ZJ-S, The plasma interleukin (IL)-35 level and frequency of circulating IL-35\u2009+\u2009regulatory B Cells are decreased in a cohort of chinese patients with new-onset systemic. nature.com. Scientific Reports, 2019 nature.com.; Available from: https:\/\/www.nature.com\/articles\/s41598-019-49748-z","DOI":"10.1038\/s41598-019-49748-z"},{"key":"2271_CR76","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/jir.2021.0147","volume":"41","author":"C Ye","year":"2021","unstructured":"Ye C, Yano H, Workman CJ, Vignali DAA. Interleukin-35: structure, function and its impact on immune-related diseases. J Interferon Cytokine Res. 2021;41:391\u2013406.","journal-title":"J Interferon Cytokine Res"},{"key":"2271_CR77","doi-asserted-by":"publisher","first-page":"2035117","DOI":"10.1080\/21645515.2022.2035117","volume":"18","author":"TK Goswami","year":"2022","unstructured":"Goswami TK, Singh M, Dhawan M, Mitra S, Emran T, Bin, Rabaan AA, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges. Hum Vaccin Immunother. 2022;18:2035117.","journal-title":"Hum Vaccin Immunother"},{"key":"2271_CR78","doi-asserted-by":"publisher","first-page":"1055805","DOI":"10.3389\/fimmu.2022.1055805","volume":"13","author":"AS Wegrzyn","year":"2023","unstructured":"Wegrzyn AS, Kedzierska AE, Obojski A. Identification and classification of distinct surface markers of T regulatory cells. Front Immunol. 2023;13:1055805.","journal-title":"Front Immunol"},{"key":"2271_CR79","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41392-024-01988-w","volume":"9","author":"S-W Huang","year":"2024","unstructured":"Huang S-W, Jiang W, Xu S, Zhang Y, Du J, Wang Y-Q, et al. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. Signal Transduct Target Ther. 2024;9:285.","journal-title":"Signal Transduct Target Ther"},{"key":"2271_CR80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45\u201356.","journal-title":"Nat Immunol"},{"key":"2271_CR81","doi-asserted-by":"publisher","first-page":"1144563","DOI":"10.1155\/2022\/1144563","volume":"2022","author":"C Lei","year":"2022","unstructured":"Lei C, Jiang J, Zhang Y, Xiong G. Role and function of regulatory T cell in chronic rhinosinusitis with nasal polyposis. J Immunol Res. 2022;2022:1144563.","journal-title":"J Immunol Res"},{"key":"2271_CR82","first-page":"32","volume":"63","author":"CF Yeh","year":"2025","unstructured":"Yeh CF, Lan MY, Lin CC, Hung YW, Huang WH, Lai YL. Dual blockade of IL-4 and IL-13 with dupilumab ameliorates sensorineural olfactory dysfunction in mice with eosinophilic sinonasal inflammation. Rhinology. 2025;63:32\u201342.","journal-title":"Rhinology"},{"key":"2271_CR83","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392:1710\u201320.","journal-title":"N Engl J Med"},{"key":"2271_CR84","doi-asserted-by":"publisher","first-page":"2000751","DOI":"10.1183\/13993003.00751-2020","volume":"57","author":"J L\u00f3pez-Abente","year":"2021","unstructured":"L\u00f3pez-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3\u2009+\u2009Tregs. Eur Respir J. 2021;57:2000751.","journal-title":"Eur Respir J"},{"key":"2271_CR85","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40265-025-02151-7","volume":"85","author":"M Shirley","year":"2025","unstructured":"Shirley M, Stapokibart. First Approval Drugs 2025 855. 2025;85:715\u201320. https:\/\/doi.org\/10.1007\/s40265-025-02151-7.","journal-title":"First Approval Drugs 2025 855"},{"key":"2271_CR86","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2025.12515","volume":"334","author":"S Shen","year":"2025","unstructured":"Shen S, Yan B, Wang M, Wu D, Piao Y, Tang J, et al. Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 randomized clinical trial. JAMA. 2025;334:962.","journal-title":"JAMA"},{"key":"2271_CR87","doi-asserted-by":"publisher","first-page":"110721","DOI":"10.1016\/j.isci.2024.110721","volume":"27","author":"W Liu","year":"2024","unstructured":"Liu W, Zhao Y, He Y, Yan X, Yu J, Song Q, et al. Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation. iScience. 2024;27:110721.","journal-title":"iScience"},{"key":"2271_CR88","unstructured":"What is the mechanism of action of Stapokibart?. (2026). Available from: https:\/\/synapse.patsnap.com\/article\/what-is-the-mechanism-of-action-of-stapokibart"},{"key":"2271_CR89","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.eclinm.2023.102076","volume":"61","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yan B, Shen S, Song X, Jiang Y, Shi L, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. eClinicalMedicine. 2023;61:102076.","journal-title":"eClinicalMedicine"},{"key":"2271_CR90","doi-asserted-by":"publisher","first-page":"9489","DOI":"10.3390\/ijms24119489","volume":"24","author":"G Ryu","year":"2023","unstructured":"Ryu G, Lee E, Park SI, Park M, Hong SD, Jung YG, et al. The mechanism of action and clinical efficacy of low-dose long-term macrolide therapy in chronic rhinosinusitis. Int J Mol Sci. 2023;24:9489.","journal-title":"Int J Mol Sci"},{"key":"2271_CR91","doi-asserted-by":"crossref","unstructured":"Zheng R, Yuan T, Yang Q. Leukotriene receptor antagonists. Chronic Rhinosinusitis: the Mucosal Concept. 2023;333\u20135. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554445\/","DOI":"10.1007\/978-981-16-0784-4_41"},{"key":"2271_CR92","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128:997\u20131009.","journal-title":"J Clin Invest"},{"key":"2271_CR93","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/cea.12472","volume":"45","author":"KE Hulse","year":"2015","unstructured":"Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45:328\u201346.","journal-title":"Clin Exp Allergy"},{"key":"2271_CR94","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","volume":"192","author":"WW Stevens","year":"2015","unstructured":"Stevens WW, Ocampo CJ, Berdnikovs S, Sakashita M, Mahdavinia M, Suh L, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med. 2015;192:682\u201394.","journal-title":"Am J Respir Crit Care Med"},{"key":"2271_CR95","doi-asserted-by":"publisher","first-page":"E110","DOI":"10.1002\/lary.27658","volume":"129","author":"GT Zhai","year":"2019","unstructured":"Zhai GT, Li JX, Zhang XH, Liao B, Lu X, Liu Z. Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps. Laryngoscope. 2019;129:E110\u20137.","journal-title":"Laryngoscope"},{"key":"2271_CR96","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nri3476","volume":"13","author":"WC Gause","year":"2013","unstructured":"Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13:607\u201314.","journal-title":"Nat Rev Immunol"},{"key":"2271_CR97","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","volume":"18","author":"PJ Barnes","year":"2018","unstructured":"Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18:454\u201366.","journal-title":"Nat Rev Immunol"},{"key":"2271_CR98","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"2271_CR99","doi-asserted-by":"crossref","unstructured":"Maniscalco M, Fuschillo S, Mormile I, Detoraki A, Sarnelli G, de Paulis A et al. Exhaled nitric oxide as biomarker of type 2 diseases. Cells. 2023;12:1518.","DOI":"10.3390\/cells12212518"},{"key":"2271_CR100","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London England). 2016;388:2128\u201341.","journal-title":"Lancet (London England)"},{"key":"2271_CR101","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London England). 2016;388:2115\u201327.","journal-title":"Lancet (London England)"},{"key":"2271_CR102","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbrc.2005.06.084","volume":"334","author":"M Ritter","year":"2005","unstructured":"Ritter M, G\u00f6ggel R, Chaudhary N, Wiedenmann A, Jung B, Weith A, et al. Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation. Biochem Biophys Res Commun. 2005;334:254\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"2271_CR103","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","volume":"118","author":"G Takayama","year":"2006","unstructured":"Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98\u2013104.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR104","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jaci.2011.07.049","volume":"128","author":"K Van Crombruggen","year":"2011","unstructured":"Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy Clin Immunol. 2011;128:728\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR105","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.jaci.2022.02.022","volume":"149","author":"AJ Psaltis","year":"2022","unstructured":"Psaltis AJ, Mackenzie BW, Cope EK, Ramakrishnan VR. Unravelling the role of the microbiome in chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149:1513\u201321.","journal-title":"J Allergy Clin Immunol"},{"key":"2271_CR106","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1089\/jir.2015.0015","volume":"35","author":"DV Sawant","year":"2015","unstructured":"Sawant DV, Hamilton K, Vignali DAA. Interleukin-35: expanding its job profile. J Interf Cytokine Res. 2015;35:499.","journal-title":"J Interf Cytokine Res"},{"key":"2271_CR107","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1141\u201353.","journal-title":"Lancet Respir Med"},{"key":"2271_CR108","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","volume":"66","author":"CJ Workman","year":"2009","unstructured":"Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DAA. The development and function of regulatory T cells. Cell Mol Life Sci C. 2009;66:2603.","journal-title":"Cell Mol Life Sci C"},{"key":"2271_CR109","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/ijc.31382","volume":"143","author":"M Teymouri","year":"2018","unstructured":"Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer. 2018;143:2105\u201315.","journal-title":"Int J Cancer"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:03:08Z","timestamp":1780434188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02271-0","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"127"}}